SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off following quarterly earnings that investors are viewing as a 'sell the news' event despite reported growth. The community is actively debating whether the stock is a deep-value buying opportunity or if the current momentum suggests a continued slide, with many traders questioning why the market reaction has been so severe given the company's raised guidance.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing intense community focus ahead of its quarterly earnings release, with investors closely watching for updates on its Neutron rocket program, defense contract conversions, and revenue growth. Sentiment remains bullish, as market participants look past recent volatility, citing the company's expanding backlog and position as a key strategic partner in the growing space defense and satellite infrastructure sectors.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics is trending as investors react to a significant regulatory update regarding tabelecleucel, with community discourse divided between optimism over the path to FDA approval and skepticism regarding the company's financial stability and dilution risks. Traders are closely monitoring the stock's volatility and institutional activity, while debating whether the current price action reflects a true recovery or potential downside volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge in social media activity as investors position themselves ahead of the upcoming earnings release, debating whether the stock will trigger a major short squeeze given its high short interest and institutional accumulation. The community remains sharply divided, with bulls pointing to strong AI growth narratives and potential partnerships, while bears continue to raise concerns regarding the company's path to profitability and recent valuation run-up.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is experiencing significant volatility as investors weigh strong revenue growth and a record backlog against concerns regarding tightening profit margins and ongoing cash flow challenges. The community is actively debating the company's position as a key infrastructure provider for AI data centers versus its persistent struggle to achieve consistent bottom-line profitability.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is facing intense volatility following its recent earnings report, as investors weigh impressive revenue growth and aggressive expansion plans against concerns over margin compression and a potential slowdown in historical growth rates. The community remains sharply divided, with bulls viewing the pullback as a prime accumulation opportunity for a high-growth brand, while bears argue that the valuation remains too steep relative to the cooling consumer environment.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending as investors debate the sustainability of the AI infrastructure cycle following reports of an $18 billion financing hurdle for an OpenAI custom chip project. While the market digests potential risks to hyperscaler capital commitments, the community remains divided between those viewing the pullback as a valuation reset within a persistent expansion cycle and those concerned about potential bubbles in AI compute demand.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is currently trending as investors weigh strong profitability and recent AAA-rated funding successes against market volatility and geopolitical concerns affecting the fintech sector. While the community is actively debating the stock's long-term valuation potential and the impact of the ongoing leadership transition, sentiment remains divided between those betting on an institutional re-rating and short-term traders reacting to intense short interest.

Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.

Agilon Health Inc

Agilon Health is seeing intense trading volume and community speculation driven by a combination of low-float volatility and aggressive short-squeeze sentiment. Investors are closely tracking institutional positioning and technical momentum, with discussions heavily focused on potential price expansion targets and the stock's ability to maintain high daily trading activity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the focus of investor attention as it faces high-stakes earnings after a round of workforce reductions and ongoing debate surrounding the Clarity Act. Market participants are actively weighing concerns about the company's cost structure and competitive positioning against bullish sentiment regarding institutional adoption and its evolving role in financial infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Teladoc Health (NYSE:TDOC) Price Target Raised to $7.00 at Citigroup

Citigroup lifted their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a "neutral" rating in a report on Tuesday...

TDOC Q1 Earnings Miss, Revenues Down Y/Y on BetterHelp Weakness

Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.

Teladoc Health Q1 Earnings Call Highlights

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company's guidance for both revenue and Adjusted...

Teladoc Health (NYSE:TDOC) Stock Price Up 7.7%  - Here's Why

Teladoc Health (NYSE:TDOC) Trading Up 7.7% - What's Next...

Teladoc Health Target of Unusually Large Options Trading (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) was the recipient of some unusual options trading on Friday. Traders acquired 28,675 call options on the company. This represents an increase of 102% compared to the average volume of 14,214 call options...

HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

<ul class="summary-bullets"><li>Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding.</li><li>The 503B Bulk List features drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines.</li><li>The agency said there is insufficient evidence to justify broader access to compounded versions.</li></ul>The U.S. Food and Drug Administration, on Thursday, issued a proposal to exclude several popular weight-loss and diabetes drugs from its 503B bulks list, limiting how they can be compounded by outsourcing facilities.Semaglutide, the key ingredient in Novo Nordisk’s (NVO) Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly (LLY) as Zepbound and Mounjaro, would be excluded from bulk compounding. The Liraglutide.<h2 class="st-heading-2">FDA Sees No Clinical Need For Compounding Weight Loss Drugs</h2>The 503B Bulk List is an FDA-approved list of drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines. In most cases, facilities can only compound drugs from bulk ingredients if they appear on this list or if the drug is officially in shortage.After reviewing available data, the FDA said it found no clear clinical need to allow compounding of these drugs from raw ingredients. The agency added that its decision is based on patient safety and medical necessity, noting that there is insufficient evidence to justify broader access to compounded versions.“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary.<h2 class="st-heading-2">FDA’s Concerns With Compounded Weight Loss Drugs</h2>The agency has been vocal about its issue with compounded weight-loss drugs. In February, the FDA said it intends to tighten rules around GLP-1 ingredients used in compounded medicines, citing concerns about quality, safety, and possible legal issues. Compounded drugs are not reviewed or approved by the FDA.The agency <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-hours-fda-chief-warns-of-swift-action-on-copycat-drugs-after-novo-semaglutide-knockoff-launch/cZbnUBER4nQ">added</a> that compounded GLP-1 drugs should be used only when a patient’s needs cannot be met by an approved treatment. It also flagged risks such as improper storage, dosing mistakes, and counterfeit or misleadingly marketed products.Earlier this year, Novo Nordisk sued Hims &amp; Hers (HIMS) for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug. However, the two companies later reconciled,<a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">&nbsp;teaming</a> up to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices on the telehealth platform.Meanwhile, shares of LLY and NVO gained 9% and 5%, respectively, while HIMS edged 0.5% lower and Teladoc Health (TDOC) fell 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-up-earnings-mounjaro-zepbound/cZBMJq7Re4X">LLY Stock Up 7% Pre-Market As Mounjaro, Zepbound Sales Smash Expectations – Retail Bets On Run Toward $1,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Moves To Block Compounded Versions Of Popular Weight-Loss Drugs – NVO, LLY Stocks Gain

The FDA issued a proposal to exclude several popular weight-loss and diabetes drugs from being compounded by outsourcing facilities.

Equity

Teladoc Health (NYSE:TDOC) Shares Gap Down on Disappointing Earnings

Teladoc Health (NYSE:TDOC) Shares Gap Down After Earnings Miss...

Teladoc Health (NYSE:TDOC) Issues Earnings Results, Misses Estimates By $0.02 EPS

Teladoc Health (NYSE:TDOC - Get Free Report) issued its earnings results on Wednesday. The health services provider reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by...

Here's What Key Metrics Tell Us About Teladoc (TDOC) Q1 Earnings

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Current Price	$6.90
Prev Close	$6.80
Open	$6.85
Dividend Yield	0.00%
50-Day Moving Average	$5.54
Beta	1.55
Avg. Volume	4.67M
PE Ratio	-7.06

52-Week High	$9.77
52-Week Low	$4.40
Market Capitalization	$1.23B
EPS (Annual)	-$1.14
Price to Book	0.92
Revenue Per Employee	$451,781.61

TDOC
Teladoc Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TDOC News

TDOCTeladoc Health Inc